Template:Parenteral potencies and durations of progestogens

From HandWiki
v · d · e Parenteral potencies and durations of progestogens
Progestogen Form Major brand names Class TFD
(14 days)		 POIC-D
(2–3 months)		 CIC-D
(month)		 Duration
Algestone acetophenide Oil solution Perlutal, Topasel, Yectames Pregnane ? – 75–150 mg 100 mg ≈ 14–32 days
Cyproterone acetate Oil solution Androcur Depot Pregnane ? – – 300 mg ≈ 20 days
Dydrogesteronea Aqueous suspension – Retropregnane ? – – 100 mg ≈ 16–38 days
Gestonorone caproate Oil solution Depostat, Primostat Norpregnane 50 mg – – 25–50 mg ≈ 8–13 days
Hydroxyprogesterone acetatea Aqueous suspension – Pregnane 350 mg – – 150–350 mg ≈ 9–16 days
Hydroxyprogesterone caproate Oil solution Delalutin, Proluton, Makena Pregnane 250–500 mgb – 250–500 mg 65–500 mg ≈ 5–21 days
Levonorgestrel butanoatea Aqueous suspension – Gonane ? – – 5–50 mg ≈ 3–6 months
Lynestrenol phenylpropionatea Oil solution – Estrane ? – – 50–100 mg ≈ 14–30 days
Medroxyprogesterone acetate Aqueous suspension Depo-Provera Pregnane 50–100 mg 150 mg 25 mg 50–150 mg ≈ 14–50+ days
Megestrol acetate Aqueous suspension Mego-E Pregnane ? – 25 mg 25 mg ≈ >14 daysc
Norethisterone enanthate Oil solution Noristerat, Mesigyna Estrane 100–200 mg 200 mg 50 mg 50–200 mg ≈ 11–52 days
Oxogestone phenylpropionatea Oil solution – Norpregnane ? – – 100 mg ≈ 19–20 days
Progesterone Oil solution Progestaject, Gestone, Strone Pregnane 200 mgb – – 25–350 mg ≈ 2–6 days
Aqueous suspension Agolutin Depot Pregnane 50–200 mg – – 50–300 mg ≈ 7–14 days
Note: All by intramuscular or subcutaneous injection. All are synthetic except for P4, which is bioidentical. P4 production during the luteal phase is ~25 (15–50) mg/day. The OID of OHPC is 250 to 500 mg/month. Footnotes: a = Never marketed by this route. b = In divided doses (2 × 125 or 250 mg for OHPC, 10 × 20 mg for P4). c = Half-life is ~14 days. Sources: Main: [1][2][3][4][5][6][7][8] Additional: [9][10][11][12][13][14][15][16][17][18]
Template documentation

See also

References

  1. ↑ Knörr, Karl; Beller, Fritz K.; Lauritzen, Christian (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0. https://books.google.com/books?id=ACybBwAAQBAJ&pg=PA214. 
  2. ↑ Knörr, Karl; Knörr-Gärtner, Henriette; Beller, Fritz K.; Lauritzen, Christian (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9. https://books.google.com/books?id=tpmgBgAAQBAJ&pg=PA583. 
  3. ↑ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 554–. ISBN 978-3-642-96158-8. https://books.google.com/books?id=DAgJCAAAQBAJ&pg=PA554. 
  4. ↑ Horský, Jan; Presl, Jiří (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8195-9. https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA313. 
  5. ↑ Joachim Ufer (1969). The Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics. de Gruyter. p. 49. https://books.google.com/books?id=G8VsAAAAMAAJ. "17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle." 
  6. ↑ Willibald Pschyrembel (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598,601. ISBN 978-3-11-150424-7. https://books.google.com/books?id=vVaTnHDFzZ0C&pg=PA598. 
  7. ↑ "Effects, Duration of Action and Metabolism in Man". Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. II. Pergamon Press. September 1972. pp. 13–24. ISBN 978-0080168128. OCLC 278011135. https://books.google.com/books?id=Nv5sAAAAMAAJ. 
  8. ↑ Milan Rastislav Henzl; John A. Edwards (10 November 1999). "Pharmacology of Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 101–132. ISBN 978-0-8247-8291-7. https://books.google.com/books?id=vGJJHsJASekC. 
  9. ↑ "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception 49 (4): 361–85. April 1994. doi:10.1016/0010-7824(94)90033-7. PMID 8013220. 
  10. ↑ "Existing once-a-month combined injectable contraceptives". Contraception 49 (4): 293–301. April 1994. doi:10.1016/0010-7824(94)90029-9. PMID 8013216. 
  11. ↑ "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control". World J Pharm Pharm Sci 3 (10): 364–392. 2014. ISSN 2278-4357. http://www.wjpps.com/download/article/1412071798.pdf. 
  12. ↑ "Pharmacokinetics of Contraceptive Steroids in Humans". Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. 1986. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2. https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67. 
  13. ↑ Becker, H.; Düsterberg, B.; Klosterhalfen, H. (1980). "Bioverfügbarkeit von Cyproteronacetat nach oraler und intramuskulärer Applikation bei Männern". Urologia Internationalis 35 (6): 381–385. doi:10.1159/000280353. ISSN 1423-0399. 
  14. ↑ Moltz, L.; Haase, F.; Schwartz, U.; Hammerstein, J. (2008). "Die Behandlung androgenisierter Frauen mit intramuskulär applizierbarem Cyproteronacetat". Geburtshilfe und Frauenheilkunde 43 (05): 281–287. doi:10.1055/s-2008-1036893. ISSN 0016-5751. 
  15. ↑ "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology. April 1986. http://en.cnki.com.cn/Article_en/CJFDTOTAL-GLYZ198604003.htm. "The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days.". 
  16. ↑ Benno Clemens Runnebaum; Thomas Rabe; Ludwig Kiesel (6 December 2012). Female Contraception: Update and Trends. Springer Science & Business Media. pp. 429–. ISBN 978-3-642-73790-9. https://books.google.com/books?id=LtT6CAAAQBAJ&pg=PA429. 
  17. ↑ Paolo Giovanni Artini; Andrea R. Genazzani; Felice Petraglia (11 December 2001). Advances in Gynecological Endocrinology. CRC Press. pp. 105–. ISBN 978-1-84214-071-0. https://books.google.com/books?id=dknDdAonzlUC&pg=PA105. 
  18. ↑ Varney's Midwifery. Jones & Bartlett Publishers. 21 October 2013. pp. 495–. ISBN 978-1-284-02542-2. https://books.google.com/books?id=dbaNAQAAQBAJ&pg=PA495. 
Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages.
Subpages of this template.
Retrieved from "https://handwiki.org/wiki/index.php?title=Template:Parenteral_potencies_and_durations_of_progestogens&oldid=15637"